- Zacks•17 hours ago
Cytokinetics (CYTK) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
- Zacks•13 days ago
Cytokinetics (CYTK) reported that it has completed patient enrollment in the phase III amyotrophic lateral sclerosis study on tirasemtiv.
- GlobeNewswire•14 days agoCytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2016-- Cytokinetics, Inc. today announced the completion of patient enrollment in VITALITY-ALS, an international Phase 3 clinical trial of tirasemtiv in patients with ...
Cytokinetics, Incorporated (CYTK)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||12.00 - 12.19|
|52wk Range||6.00 - 13.18|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-11.27|
|Avg Vol (3m)||331,741|
|Dividend & Yield||N/A (N/A)|